Eugen Leo
Corporate Officer/Principal presso Ruprecht-Karls-Universität Heidelberg
Relazioni attive
| Nome | Sesso | Età | Società collegate | Collaborazione |
|---|---|---|---|---|
| Erich Schlick | M | 72 |
Ruprecht-Karls-Universität Heidelberg
| - |
| Markus Hecker | M | - |
Ruprecht-Karls-Universität Heidelberg
| - |
| René Rückert | M | - |
Isarna Therapeutics GmbH
 Isarna Therapeutics GmbH BiotechnologyHealth Technology Isarna Therapeutics GmbH engages in developing selective TGF-ß inhibitors. It works on a pipeline of novel oligonucleotides and combination modalities to transcend clinical response and improve patient outcome. The company focuses on biopharmaceutical research, pipeline development, and partnering and licensing programs. Isarna Therapeutics was founded by Karl-Hermann Schlingensiepen and Reimar Schlingensiepen in 1998 and is headquartered in Munich, Germany. | 6 anni |
| Ernst Biekert | M | 99 |
Ruprecht-Karls-Universität Heidelberg
| 56 anni |
| Mohsen M. Sohi | M | 65 |
Ruprecht-Karls-Universität Heidelberg
| - |
| Uwe Bicker | M | 79 |
Ruprecht-Karls-Universität Heidelberg
| 13 anni |
| Thorlef Spickschen | M | 83 |
Ruprecht-Karls-Universität Heidelberg
| - |
| Paul Kirchhof | M | - |
Ruprecht-Karls-Universität Heidelberg
| - |
| Margret Suckale | F | 68 |
Ruprecht-Karls-Universität Heidelberg
| - |
| Malte Bahner | M | 61 |
Ruprecht-Karls-Universität Heidelberg
| - |
| Magnus von Knebel Döberitz | M | - |
Ruprecht-Karls-Universität Heidelberg
| - |
| Michael Heinz | M | 60 |
Ruprecht-Karls-Universität Heidelberg
| 7 anni |
| Götz M. Richter | M | - |
Ruprecht-Karls-Universität Heidelberg
| - |
| Andreas Wentzensen | M | - |
Ruprecht-Karls-Universität Heidelberg
| - |
| Gerd Auffarth | M | 59 |
Ruprecht-Karls-Universität Heidelberg
| 13 anni |
| Paul Scigalla | M | 79 |
Ruprecht-Karls-Universität Heidelberg
| 32 anni |
Grafico relazionale
Relazione in diverse aziende
Relazioni precedenti
| Nome | Sesso | Età | Società collegate | Collaborazione |
|---|---|---|---|---|
| Stefanos Theoharis | M | 47 |
Isarna Therapeutics GmbH
Isarna Therapeutics GmbH BiotechnologyHealth Technology Isarna Therapeutics GmbH engages in developing selective TGF-ß inhibitors. It works on a pipeline of novel oligonucleotides and combination modalities to transcend clinical response and improve patient outcome. The company focuses on biopharmaceutical research, pipeline development, and partnering and licensing programs. Isarna Therapeutics was founded by Karl-Hermann Schlingensiepen and Reimar Schlingensiepen in 1998 and is headquartered in Munich, Germany. | 2 anni |
| Michel Janicot | M | - |
Isarna Therapeutics GmbH
Isarna Therapeutics GmbH BiotechnologyHealth Technology Isarna Therapeutics GmbH engages in developing selective TGF-ß inhibitors. It works on a pipeline of novel oligonucleotides and combination modalities to transcend clinical response and improve patient outcome. The company focuses on biopharmaceutical research, pipeline development, and partnering and licensing programs. Isarna Therapeutics was founded by Karl-Hermann Schlingensiepen and Reimar Schlingensiepen in 1998 and is headquartered in Munich, Germany. | - |
Statistiche
| Paese | Relazioni | % del totale |
|---|---|---|
| Germania | 18 | 100.00% |
Età delle relazioni
Attive
Scorse
Uomo
Donna
Amministratori
Dirigenti
Provenienza delle relazioni
- Borsa valori
- Insiders
- Eugen Leo
- Contatti personali
